Compare · ABBV vs MPLT
ABBV vs MPLT
Side-by-side comparison of AbbVie Inc. (ABBV) and MapLight Therapeutics Inc. (MPLT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and MPLT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $447.67B, about 274.3x MPLT ($1.63B).
- Over the past year, ABBV is up 38.1% and MPLT is up 102.2% - MPLT leads by 64.1 points.
- ABBV has been more active in the news (13 items in the past 4 weeks vs 11 for MPLT).
- ABBV has more recent analyst coverage (25 ratings vs 12 for MPLT).
- Company
- AbbVie Inc.
- MapLight Therapeutics Inc.
- Price
- $255.30+0.72%
- $36.85+2.20%
- Market cap
- $447.67B
- $1.63B
- 1M return
- +17.92%
- +28.19%
- 1Y return
- +38.12%
- +102.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2025
- News (4w)
- 13
- 11
- Recent ratings
- 25
- 12
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Latest ABBV
- Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
- SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
- SEC Form 4 filed by Director Rapp Edward J
- SEC Form 4 filed by Director Quaggin Susan E
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- FDA Approval for SKYRIZI issued to ABBVIE INC
Latest MPLT
- BMO Capital Markets initiated coverage on MapLight Therapeutics with a new price target
- Chief Discovery Officer Kreitzer Anatol sold $1,345,894 worth of Voting Common Stock (36,284 units at $37.09) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 174,906 units (SEC Form 4) to cover withholding tax
- CAO and Interim CFO Gillis Jonathan sold $1,372,668 worth of Voting Common Stock (36,979 units at $37.12) as part of a pre-agreed trading plan, decreasing direct ownership by 20% to 144,240 units (SEC Form 4) to satisfy tax liability
- Chief Executive Officer Kroeger Christopher A. sold $5,443,722 worth of Voting Common Stock (147,639 units at $36.87), decreasing direct ownership by 11% to 1,246,455 units (SEC Form 4) to satisfy withholding obligation
- Chief Scientific Officer Lillie James Woodruff sold $673,636 worth of Voting Common Stock (18,267 units at $36.88), decreasing direct ownership by 8% to 224,462 units (SEC Form 4) to satisfy withholding obligation
- General Counsel Hanson Kristopher sold $607,870 worth of Voting Common Stock (16,508 units at $36.82), decreasing direct ownership by 10% to 145,823 units (SEC Form 4) to cover taxes
- Chief Medical Officer Foff Erin Pennock sold $1,734,490 worth of Voting Common Stock (47,158 units at $36.78) as part of a pre-agreed trading plan, decreasing direct ownership by 14% to 298,901 units (SEC Form 4) (withholding obligation)
- SEC Form 144 filed by MapLight Therapeutics Inc.
- SEC Form 144 filed by MapLight Therapeutics Inc.
- SEC Form 144 filed by MapLight Therapeutics Inc.